Research progress of targeting PD-1/PD-L1 in immunotherapy for non-small-cell lung cancer / 肿瘤研究与临床
Cancer Research and Clinic
; (6): 711-713, 2015.
Article
de Zh
| WPRIM
| ID: wpr-483197
Bibliothèque responsable:
WPRO
ABSTRACT
Lung cancer is the leading cause of cancer-related death in the world.PD-1 is a member of the CD28 family expressed on the surface of a variety of immune cells.PD-L1, one of PD-1 ligands, plays a pivotal role in the ability of tumor cells to evade the host immune system.A recent study showed that signaling via mutant EGFR in lung tumor cells upregulates directly tumor PD-L1 expression.In this review, the clinical significance of the PD-1/PD-L1 pathway in immunotherapy for non-small-cell lung cancer (NSCLC) and the relevance to targeted therapy were summarized.
Texte intégral:
1
Indice:
WPRIM
langue:
Zh
Texte intégral:
Cancer Research and Clinic
Année:
2015
Type:
Article